StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Shantou Institute of Ultrasonic Instruments Co., Ltd. logo

Shantou Institute of Ultrasonic Instruments Co., Ltd.

301602 · XSHE · Medical Devices · China

Market Capitalization9.20B CNY
Trailing P/E58.97 CNY
52-Week Change-24.59 CNY
Forward Annual Dividend Yield0.48%

Shantou Institute of Ultrasonic Instruments Co., Ltd. is a prominent entity in the field of medical technology, specifically focusing on the development and production of ultrasonic diagnostic and therapeutic equipment. The company's primary function is to innovate and enhance medical imaging solutions that aid in non-invasive diagnostic procedures. It plays a crucial role in healthcare sectors, influencing various medical fields like cardiology, oncology, and obstetrics by providing advanced ultrasound imaging technology. Headquartered in Shantou, China, the company is recognized for its commitment to quality and technological advancement, contributing significantly to the improvement of medical standards both locally and internationally. Its market significance lies in its ability to deliver precise imaging products that are essential for accurate patient diagnosis and treatment planning, thereby supporting the broader objective of elevating healthcare delivery through state-of-the-art equipment.

Industry

Medical Devices

Healthcare sector · China

Stories

Structural patterns identified in Shantou Institute of Ultrasonic Instruments Co., Ltd.

No stories identified yet.

Key Metrics

Market Capitalization
9.20BCNY
NormalMar 18, 2026
Trailing P/E
58.97CNY
AboveNormalMar 18, 2026
Revenue (TTM)
361.65MCNY
NormalMar 18, 2026
Profit Margin
36.73%
NormalMar 18, 2026
52-Week Change
-24.59CNY
ExtremeMar 18, 2026
Forward Annual Dividend Yield
0.48%
NormalMar 18, 2026
Forward Yield
0.48%
Annual Rate
CNY 0.10
Paid unknown
Payout Ratio
28.3%
Sustainable
Loading dividend history...

Track Record

Frequency
Unknown
Payback Period
196.1 yr
Years to recoup investment via dividends alone

Upcoming

Ex-Dividend Date
Jun 19, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation7
Market Capitalization
9.20BCNY
NormalMar 18, 2026
Enterprise Value
7.99BCNY
NormalMar 18, 2026
Trailing P/E
58.97CNY
AboveNormalMar 18, 2026
Price to Sales (TTM)
25.14CNY
AboveNormalMar 18, 2026
Price to Book (MRQ)
6.99CNY
NormalMar 18, 2026
Enterprise to Revenue
22.09CNY
AboveNormalMar 18, 2026
Enterprise to EBITDA
57.25CNY
AboveNormalMar 18, 2026
Profitability & Growth51
Gross Margin
75.52%
NormalMar 18, 2026
Profit Margin
36.73%
NormalMar 18, 2026
Operating Margin
33.47%
NormalMar 18, 2026
Return on Assets (TTM)
0.1447CNY
NormalMar 18, 2026
Return on Equity (TTM)
0.1672CNY
NormalMar 18, 2026
Revenue (TTM)
361.65MCNY
NormalMar 18, 2026
Revenue per Share (TTM)
0.8830CNY
NormalMar 18, 2026
Quarterly Revenue Growth
-0.3530CNY
NormalMar 18, 2026
Gross Profit (TTM)
262.48MCNY
NormalMar 18, 2026
EBITDA
167.30MCNY
ExtremeMar 18, 2026
Net Income (TTM)
132.85MCNY
NormalMar 18, 2026
Quarterly Earnings Growth (YoY)
-0.5330CNY
BelowNormalMar 18, 2026
Operating Cash Flow (TTM)
103.25MCNY
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
145.58MCNY
NormalMar 18, 2026
Forward Annual Dividend Rate
0.1000CNY
NormalMar 18, 2026
Forward Annual Dividend Yield
0.48%
NormalMar 18, 2026
Trailing Annual Dividend Rate
0.1020CNY
NormalMar 18, 2026
Trailing Annual Dividend Yield
0.48%
NormalMar 18, 2026
Payout Ratio
0.2833CNY
NormalMar 18, 2026
Revenue
375.81M
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
109.79M
NormalFY2024 · Dec 31, 2024
Gross Profit
266.03M
NormalFY2024 · Dec 31, 2024
Operating Income
142.61M
NormalFY2024 · Dec 31, 2024
Pre-tax Income
165.39M
NormalFY2024 · Dec 31, 2024
Income Tax Expense
19.82M
NormalFY2024 · Dec 31, 2024
Net Income
145.58M
NormalFY2024 · Dec 31, 2024
EBIT
142.61M
NormalFY2024 · Dec 31, 2024
ebitda-income
159.25M
NormalFY2024 · Dec 31, 2024
Research & Development
50.04M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
25.75M
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
5.77M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
14.16M
NormalFY2024 · Dec 31, 2024
EPS (Basic)
0.4000
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
0.4000
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
363.94MShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
363.94MShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
145.58M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
104.06M
NormalFY2024 · Dec 31, 2024
Free Cash Flow
113.73M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
202.48M
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
145.58M
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
-19.21M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
-30.68M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
8.37M
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-18.67M
NormalFY2024 · Dec 31, 2024
Purchase of Investments
-1.99B
NormalFY2024 · Dec 31, 2024
Sale of Investments
1.98B
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
-27.87M
NormalFY2024 · Dec 31, 2024
Other Financing Charges
-600.00K
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-600.00K
NormalFY2024 · Dec 31, 2024
Financial Strength27
Shares Outstanding
428.33MShares
NormalMar 18, 2026
Float Shares
75.13MCNY
NormalMar 18, 2026
% Held by Insiders
0.8265CNY
AboveNormalMar 18, 2026
% Held by Institutions
0.0537CNY
NormalMar 18, 2026
Total Cash (MRQ)
1.10BCNY
NormalMar 18, 2026
Total Cash per Share (MRQ)
2.57CNY
NormalMar 18, 2026
Total Debt (MRQ)
0.00CNY
NormalMar 18, 2026
Total Debt to Equity (MRQ)
0.00CNY
NormalMar 18, 2026
Current Ratio (MRQ)
12.71CNY
ExtremeMar 18, 2026
Book Value per Share (MRQ)
3.04CNY
NormalMar 18, 2026
Total Assets
1.01B
NormalFY2024 · Dec 31, 2024
Total Current Assets
879.67M
NormalFY2024 · Dec 31, 2024
Total Liabilities
135.38M
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
126.37M
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
15.60M
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
119.77M
NormalFY2024 · Dec 31, 2024
Cash
563.38M
NormalFY2024 · Dec 31, 2024
Cash Equivalents
144.39M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
707.77M
NormalFY2024 · Dec 31, 2024
Accounts Receivable
48.33M
NormalFY2024 · Dec 31, 2024
Inventory
108.88M
NormalFY2024 · Dec 31, 2024
Accounts Payable
22.37M
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
933.39K
NormalFY2024 · Dec 31, 2024
Other Non-current Liabilities
6.92M
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
364.08M
NormalFY2024 · Dec 31, 2024
Retained Earnings
442.88M
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
870.66M
NormalFY2024 · Dec 31, 2024
Market & Technical8
52-Week Low
20.20CNY
NormalMar 18, 2026
52-Week High
29.48CNY
NormalMar 18, 2026
52-Week Change
-24.59CNY
ExtremeMar 18, 2026
50-Day MA
22.43CNY
NormalMar 18, 2026
200-Day MA
24.33CNY
NormalMar 18, 2026
Avg 10-Day Volume
1.21MCNY
NormalMar 18, 2026
Avg 30-Day Volume
1.51MCNY
NormalMar 18, 2026
Diluted EPS (TTM)
0.3600CNY
NormalMar 18, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.